Gi Insights

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Kyle Staller, MD, MPH Unfortunately, there are not a lot of specific pharmacologic agents for incontinent patients; however, using typical antidiarrheal therapies can be helpful for patients who have diarrhea. So what other treatment options should we know about? To learn more, join Dr. Peter Buch as he speaks with Dr. Kyle Staller, Assistant Professor of Medicine at Harvard Medical School and Director of the Gastrointestinal Motility Laboratory at Mass General.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David Liska, MD Since the 1990s, clinicians have been seeing a significant increase in colorectal cancer among young patients, who are under the age of 50. A multidisciplinary approach is key as diagnostic and treatment considerations are specific to their age. Dive in with Dr. Peter Buch as he’s joined by Dr. David Liska, Section Chief of Oncology in the Department of Colorectal Surgery at the Cleveland Clinic.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Naga Chalasani, MD With the increasing incidence and prevalence of cirrhosis in patients, healthcare professionals have to routinely consider giving anticoagulants to these patients. Understanding how we can safely administer these types of medications to cirrhosis patients is important. To learn more, tune in with Dr. Peter Buch as he speaks with Dr. Naga Chalasani, Co-Author of the article, titled “The Safety of Anticoagulants and Antiplatelet Agents in Patients with Cirrhosis,” which was published in Alimentary Pharmacology and Therapeutics in November 2022, and the David W. Crabb Professor of Gastroenterology and Hepatology at Indiana University School of Medicine in Indianapolis.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Charlton, MD Liver disease is highly prevalent in patients with type 2 diabetes, and it’s much more likely to be a clinically significant issue in these patients as well. So it’s important to evaluate patients for liver disease during routine check-ups. Dive further into the effects of liver disease in diabetic care with Dr. Peter Buch as he speaks with Dr. Michael Charlton, Professor of Medicine and Co-Director of the Transplant Institute at the University of Chicago.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Paul Kwo, MD Non-alcoholic fatty liver disease connoted that there's no alcohol contribution to the fat and didn't accurately convey the interplay between metabolic-driven cytosis, which can come from insulin resistance and all of the other metabolic dysfunction-associated inflammatory patterns, as well as the contributions of alcohol. So what do we know about patients who have metabolic dysfunction-associated steatotic liver disease (MASLD) and also consume alcohol? To learn more, join Dr. Peter Buch as he discusses this with Dr. Paul Kwo, Professor of Medicine and the Director of Hepatology at Stanford University.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Shubha Bhat, PharmD Fortunately, there are a lot of studies that have evaluated biosimilars in inflammatory bowel disease (IBD), and those all confirmed that biosimilars are safe, effective, and do not result in worsening patient outcomes. But are we using biosimilars enough in the treatment of IBD? Dive in with Dr. Mary Katherine Cheeley as she speaks with Dr. Shubha Bhat, Clinical Pharmacist in the Digestive Disease Institute at the Cleveland Clinic.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Marianna Arvanitakis, MD, PhD Patients with non-celiac gluten sensitivity can experience the same symptoms of those with celiac disease and IBS, complicating the diagnostic process. Find out how you can accurately identify and distinguish non-celiac gluten sensitivity from other digestive disorders with Dr. Peter Buch and Dr. Marianna Arvanitakis, Associate Clinical Professor in the Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology from the HUB Erasme Hospital in Brussels, Belgium.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: William Chey, MD Roughly 1 in 10 Americans suffer with some degree of constipation, and many of those patients suffer with ongoing chronic issues around constipation. So for the first time, the American Gastroenterological Association and the American College of Gastroenterology have released joint recommendations for the management of chronic idiopathic constipation (CIC). To dive into these guidelines, Dr. Peter Buch is joined by Dr. William Chey, Marvin Pollard Professor of Gastroenterology and Chief of the Department of Gastroenterology and Hepatology at the University of Michigan.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Zobair M Younossi MD, MPH, FACP, FACG, AGAF, FAASLD Guest: Alan H.B. Wu, PhD Liver disease patients are at an increased risk of major adverse cardiovascular events (MACE), which is why the doctor in today’s episode believes the multidisciplinary team plays an essential role in managing these patients. Tune in with Dr. Charles Turck as he speaks with Dr. Zobair Younossi, Chair of the Global NASH Council and Professor of Medicine at the Inova Fairfax Medical Campus in Falls Church, Virginia as well as Dr. Alan Wu, Professor in Laboratory Medicine and is Chief of the Clinical Chemistry and Toxicology Laboratories at San Francisco General Hospital.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: John Pandolfino, MD, MSCI There are a wide range of therapeutic options when it comes to personalizing your patient’s treatment approach, such as simple lifestyle modifications all the way to a surgical procedure. To learn more, tune in with Dr. Peter Buch as he speaks with Dr. John Pandolfino, Hans Popper Professor and Chief of Gastroenterology and Hepatology in the Department of Medicine at Northwestern Medicine Feinberg School of Medicine in Chicago.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Douglas Drossman, MD We all face angry and disruptive patients from time to time, making it essential to know how to properly de-escalate and handle the situation. That’s why Dr. Peter Buch speaks with Dr. Douglas Drossman, co-author of an article that was published in the American Journal of Gastroenterology titled “De-escalate, Don’t Escalate: Essential Steps to Effectively Recognize and Manage the Patient Who Is Angry and Disruptive.”

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Siddharth Singh, MD How can we use biomarkers to treat patients with ulcerative colitis? That’s the exact question the latest guideline from the American Gastroenterological Association (AGA) sought to address. Learn about this guideline and other best practices with Dr. Peter Buch and Dr. Siddharth Singh, Assistant Professor of Medicine at the University of California-San Diego and co-author of an article published in Gastroenterology in March 2023 titled “AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis.”

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Alan Bonder, MD According to the United Network for Organ Sharing (UNOS), more than 95 percent of patients are alive and doing well after a liver transplant. So what else can we learn from UNOS? Join Dr. Peter Buch as he speaks with Dr. Alan Bonder, Assistant Professor of Medicine at Harvard Medical School.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Kunal Jajoo, MD The American Gastroenterological Association (AGA) recently published updated clinical guidelines for the use of endoscopic ultrasound (EUS). Are there caveats involved with these recommendations? Join Dr. Peter Buch as he speaks with Dr. Kunal Jajoo, Assistant Professor of Medicine at Harvard Medical School, about the best utilization of EUS in clinical practice.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Suijit Janardhan, MD, PhD Diabetic patients have a significant risk for developing more advanced liver disease, and the disease that they’re particularly at risk for is steatotic liver disease. Dive into this episode to learn more with Dr. Charles Turck and Dr. Sujit Janardhan, Assistant Professor in the Department of Internal Medicine, Division of Digestive Diseases and Nutrition, and the Department of Transplant Surgery at Rush University Medical Center in Chicago.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Herbert L. Bonkovsky, MD If an elevation of delta aminolevulinic or porphobilinogen occurs in the urine more than three times what is normal, that is presumptive acute hepatic porphyria (AHP. Join the conversation as Dr. Peter Buch speaks with Dr. Herbert Bonkovsky, Professor of Medicine and Molecular Medicine and Translational Science at Wake Forest University, about his article published in Gastroenterology.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Sidney Barritt, MD Even though nonalcoholic fatty liver disease is the most common form of chronic liver disease in the United States, there are unfortunately no FDA-approved medications for this condition. That’s why Dr. Peter Buch speaks with Dr. Sidney Barritt about even more treatment strategies for nonalcoholic fatty liver disease in the second and final part of this two-episode series. Dr. Barritt is an Associate Professor of Medicine and the Director of Hepatology at the UNC Liver Center at the University of North Carolina.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Sidney Barritt, MD Even though nonalcoholic fatty liver disease is the most common form of chronic liver disease in the United States, there are unfortunately no FDA-approved medications for this condition. That’s why Dr. Peter Buch speaks with Dr. Sidney Barritt about top treatment strategies for nonalcoholic fatty liver disease in part one of this two-episode series. Dr. Barritt is an Associate Professor of Medicine and the Director of Hepatology at the UNC Liver Center at the University of North Carolina.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Marianna Arvanitakis, MD, PhD Consuming ultra-processed foods can pose many risks to your health that go beyond the GI system. Explore the risks associated with ultra-processed foods with Dr. Peter Buch and Dr. Marianna Arvanitakis, Associate Clinical Professor in the Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology from the HUB Erasme Hospital in Brussels, Belgium.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Claire Jansson-Knodell, MD When a person has a low IgA level, the tissue transglutaminase immunoglobulin A antibody is no longer a useful screening test for celiac disease. So how should we be assessing patients with an IgA deficiency? To discuss these new recommendations, Dr. Peter Buch is joined by Dr. Claire Jansson-Knodell, Gastroenterologist at the Cleveland Clinic’s Digestive Disease Institute.